Microbiota markers level in the cerebrospinal fluid of patients with multiple sclerosis and radiologically isolated syndrome

According to numerous studies, gut microbiota plays a significant role in multiple sclerosis (MS) development. However, data on changes in the gut microbiota in MS is often contradictory. The most common approach in gut microbiota research is the 16S ribosomal RNA sequencing of fecal microbiota. However, such data do not reflect the composition of the entire body microbiota. There is also a lack of data on microbiota markers in the cerebrospinal fluid (CSF) of patients with MS and predisposing conditions.

Objective: to assess the level of microbial markers in the CSF of patients with MS and radiologically isolated syndrome (RIS).

Patients and methods. We used gas chromatography-mass spectrometry (GC-MS) to evaluate microbial markers levels in eight patients with MS, five patients with RIS, and seven controls.

Results and discussion. We found an increase in microbial load in patients with MS, indicating a possible association of MS with polymicrobial infection. In particular, an increase in the content of Streptococcus markers was observed, as well as a tendency to a three-fold increase in the campesterol content (a marker of campesterol-producing microfungi) in the CSF of patients with MS, compared to the control group (diagnostic punctures, various diseases of the nervous system of a non-autoimmune or inflammatory nature, not acute states).

Conclusion. GC-MS of microbial markers can be used to assess the presence of microbial markers in the CSF. The CSF of patients with MS contains an increased amount of various microbial markers, which may indicate a possible association of MS with polymicrobial infection.

1. GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 Mar;18(3):269-85. doi: 10.1016/S1474-4422(18)30443-5. Epub 2019 Jan 21.

2. Ghasemi N, Razavi S, Nikzad E. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy. Cell J. Apr-Jun 2017;19(1):1-10. doi: 10.22074/cellj.2016.4867. Epub 2016 Dec 21.

3. Kozhieva MKh, Mel'nikov MV, Rogovsky VS, et al. Gut human microbiota and multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;117(10-2):11-9. doi: 10.17116/jnevro201711710211-19 (In Russ.).

4. Reynders T, Devolder L, Valles-Colomer M, et al. Gut microbiome variation is associated to Multiple Sclerosis phenotypic subtypes. Ann Clin Transl Neurol. 2020 Apr;7(4):406-19. doi: 10.1002/acn3.51004. Epub 2020 Mar 12.

5. Yan W, Sun C, Zheng J, et al. Efficacy of Fecal Sampling as a Gut Proxy in the Study of Chicken Gut Microbiota. Front Microbiol. 2019 Sep 13;10:2126. doi: 10.3389/fmicb.2019.02126. eCollection 2019.

6. Osipov GA, Verkhovtseva NV. Study of human microecology by mass spectromet ry of microbial markers. Benef Microbes. 2011 Mar;2(1):63-78. doi: 10.3920/BM2010.0017

7. Yang Y, Misra BB, Liang L, et al. Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer. Theranostics. 2019 May 31;9(14):4101-14. doi: 10.7150/thno.35186. eCollection 2019.

8. Ktsoyan ZA, Beloborodova NV, Sedrakyan AM, et al. Profiles of Microbial Fatty Acids in the Human Metabolome are Disease-Specific. Front Microbiol. 2011 Jan 20;1:148. doi: 10.3389/fmicb.2010.00148. eCollection 2010.

9. Osipov GA. Chromato-mass spectrometric analysis of microorganisms and communities in clinical samples for infections and dysbiosis. In: Khimicheskiy analiz v meditsinskoy diagnostike [Chemical analysis in medical diagnostics]. Moscow: Nauka; 2010 (In Russ.).

10. Osipov GA, Boiko NB, Fedosova NF, et al. Comparative gas chromatography-mass spectrometry study of the composition of microbial chemical markers in feces. Microb Ecol Health Dis. 2009;21(3-4):159-71.

11. Baranov VM, Osipov GA, Mukhamediyeva LN, et al. Otsenka mikroekologicheskogo statusa cheloveka metodom khromatomass-spektrometrii. Novaya meditsinskaya tekhnologiya MZ RF № NYU-40006. 2009 [Assessment of the microecological status of a person by chromatomass spectrometry. New medical technology of the Ministry of Health of the Russian Federation No. NYU-40006. 2009] (In Russ.).

12. Cosorich I, Dalla-Costa G, Sorini C, et al. High frequency of intestinal TH17 cells correlates with microbiota alterations and disease activity in multiple sclerosis. Sci Adv. 2017 Jul 12;3(7):e1700492. doi: 10.1126/sciadv.1700492. eCollection 2017 Jul.

13. Alonso R, Fernandez-Fernandez AM, Pisa D, Carrasco L. Multiple sclerosis and mixed microbial infections. Direct identification of fungi and bacteria in nervous tissue. Neurobiol Dis. 2018 Sep;117:42-61. doi: 10.1016/j.nbd.2018.05.022. Epub 2018 Jun 1.

14. Wang HH, Sun DW, Kuang R. Inhibition of Escherichia coli by dimethyl fumarate. Int J Food Microbiol. 2001 Apr 11;65(1-2):125-30. doi: 10.1016/s0168-1605(00)00504-3

15. Ma N, Wu Y, Xie F, et al. Dimethyl fumarate reduces the risk of mycotoxins via improving intestinal barrier and microbiota. Oncotarget. 2017 Jul 4;8(27):44625-38. doi: 10.18632/oncotarget.17886